Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Drug Company Sales Reps In India Say Firms Overcharge At Will (India)

This article was originally published in PharmAsia News

Executive Summary

An organization representing a quarter of drug company sales representatives in India accuse the firms of arbitrarily increasing the prices of their products and getting away with it. The Federation of Medical and Sales Representatives' Associations of India made the accusations in notes to leading members of Parliament. The FMRAI said some companies have hiked their prices by as much as 100 times beyond the government-ordered price caps. Some essential or popular medicines have increased by 600 percent over the past nine years, said FMRAI's joint general secretary, who called the recent voluntary price reduction a "great hoax." Authorities have tried to recover some of the alleged overcharges, but drug companies have filed 75 court challenges against the efforts. (Click here for more ) "Medical Reps Accuse Drug Firms Of Overcharging" Business Standard (India) (12/10/07)

You may also be interested in...

Komipharm In Spotlight As It Files For Emergency Trials Against Coronavirus

Komipharm files for emergency clinical trial of its investigative drug to treat coronavirus pneumonia, which is poised to become the first such study by a Korean company.

QUOTED. 27 February 2020. Michael Gibson.

Apple and Johnson & Johnson are recruiting patients into Heartline, a 150,000-patient "virtual" randomized study to evaluate how the Apple watch can improve patient outcomes by reducing risk of stroke and detect atrial fibrillation early. See what Heartline's co-chair Michael Gibson of Harvard University said about it here.

Pricing Could Help Lundbeck's Vyepti In Slow-Growing CGRP Market

After eptinezumab’s approval in the US, EVP Peter Anastasiou told Scrip it will take time to change migraine doctors’ prescribing habits, but he expects CGRP inhibitors to become mainstay preventative treatments. Vyepti’s list price is about $1,000 below its competitors’ launch prices.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts